GAMMA Investing LLC Buys Shares of 2,153 Illumina, Inc. (NASDAQ:ILMN)

GAMMA Investing LLC purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 2,153 shares of the life sciences company’s stock, valued at approximately $308,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in ILMN. Annis Gardner Whiting Capital Advisors LLC bought a new position in Illumina in the 3rd quarter worth $30,000. VisionPoint Advisory Group LLC raised its stake in shares of Illumina by 344.6% in the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock worth $34,000 after buying an additional 193 shares during the period. Wetzel Investment Advisors Inc. purchased a new position in shares of Illumina during the 4th quarter valued at about $37,000. Gradient Investments LLC grew its stake in shares of Illumina by 375.0% during the 4th quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock valued at $40,000 after acquiring an additional 225 shares during the period. Finally, North Star Investment Management Corp. raised its stake in Illumina by 183.0% during the 4th quarter. North Star Investment Management Corp. now owns 300 shares of the life sciences company’s stock worth $42,000 after acquiring an additional 194 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Buying and Selling

In other news, CEO Jacob Thaysen acquired 7,330 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was acquired at an average price of $135.29 per share, with a total value of $991,675.70. Following the completion of the purchase, the chief executive officer now directly owns 14,861 shares in the company, valued at $2,010,544.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.17% of the stock is owned by corporate insiders.

Illumina Price Performance

NASDAQ:ILMN opened at $122.87 on Thursday. The firm has a market capitalization of $19.57 billion, a price-to-earnings ratio of -16.74 and a beta of 1.19. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29. The business has a 50 day simple moving average of $132.44 and a 200-day simple moving average of $127.54. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $228.13.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same period last year, the company earned $0.14 earnings per share. Illumina’s revenue was up 3.6% on a year-over-year basis. Equities analysts forecast that Illumina, Inc. will post 0.91 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ILMN shares. TD Cowen lowered shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price target for the company. in a research report on Thursday, January 4th. Barclays increased their price target on Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a research note on Wednesday, April 10th. HSBC lowered Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, January 16th. Royal Bank of Canada reiterated an “outperform” rating and set a $253.00 target price on shares of Illumina in a research report on Tuesday, April 9th. Finally, OTR Global reissued a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, Illumina currently has a consensus rating of “Hold” and a consensus target price of $167.70.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.